IMNM Immunome, Inc.
Healthcare$21.66-5.66%ClosedMarket Cap: $2.07B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
4.16
P/S
515.71
EV/EBITDA
-6.39
DCF Value
$7.38
FCF Yield
-9.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1161.9%
Operating Margin
-5947.9%
Net Margin
-5593.8%
ROE
-51.2%
ROA
-36.2%
ROIC
-40.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-59.3M | $-53.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-72.9M | $-69.9M | $— | — |
| FY null | $6.9M | 57.4% | $-214.1M | $-212.4M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-60.1M | $-57.5M | $— | — |
| Q2 null | $4.0M | 82.1% | $-46.5M | $-43.4M | $— | — |
| Q1 null | $2.9M | 100.0% | $-44.6M | $-41.6M | $— | — |
| Q4 null | $2.7M | 100.0% | $-83.0M | $-80.2M | $— | — |
| FY null | $9.0M | 100.0% | $-305.8M | $-293.0M | $— | — |
| Q3 null | $2.9M | 100.0% | $-50.5M | $-47.1M | $— | — |
| Q2 null | $2.4M | 100.0% | $-40.0M | $-36.1M | $— | — |
| Q1 null | $1.0M | 100.0% | $-132.3M | $-129.5M | $— | — |
| Q4 2023 | $3.8M | 100.0% | $-94.7M | $-92.6M | $-4.22 | — |